David Berron is a scientific co-founder of neotiv GmbH and owns company shares. Frank Jessen reports grant support from Roche and speaker and advisor honorarium from Abbvie, AC immune, Biogen, Eisai, Grifols, Janssen, Lilly, Novo Nordisk, Roche. Matthis Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, GenOrph, AviadoBio, Biohaven, Solaxa, Biogen, Zevra, and Lilly, all unrelated to the present manuscript. All other authors report no disclosures.
